27 Sep ConjuGon gets $730K to treat infections
Madison, Wis. – Injured soldiers in Iraq and Afghanistan are becoming infected with bacteria that conventional antibiotics cannot treat, but a Madison-based company is developing counter-measures.
With a $730,000 Small Business Innovation Research (SBIR) grant from the U.S. Army in hand, ConjuGon, Inc. is continuing its development of a treatment for antibiotic-resistant bacterial infections.
“We are pleased that the U.S. Army recognizes the magnitude of our work and continues to support it,” said Sal Braico, COO of ConjuGon. “We have demonstrated, with extensive animal testing, that our novel technology can effectively kill these resistant bacteria.”
The company previously was awarded a $120,000 SBIR Phase I grant from the U.S. Army and Phase I and II SBIR grants from the National Science Foundation.
ConjuGon employs a staff of eight in the MG&E Innovation Center, where it develops anti-microbial agents to kill pathogenic bacteria while minimizing the ability of the bacteria to develop resistance.
• ConjuGon receives $500,000 to battle bacteria
• ConjuGon lands $1 million angel investment
• WARF Granted New Antibiotics Patent
• ConjuGon Awarded $250,000